SBIO

ALPS Medical Breakthroughs ETF
--

--
*Unless otherwise stated, data provided by FactSet.

SBIO Fund Description

SBIO tracks the Poliwogg Medical Breakthroughs Index, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.

SBIO Factset Analytics Insight

If you're looking for broad biotech exposure, you won't find it in SBIO; the fund targets biotech companies with drugs in Phase II and Phase III of FDA clinical trials, and limits itself to US-listed firms with market caps between $200M and $5B. SBIO also screens for sustainability—meaning constituent firms have enough cash on hand to last 2 years. Given the low historical success rates in clinical trials, the fund is a high-risk, high-reward bet on a small subset of biotech companies. SBIO's Tradability isn't bad for a specialty fund, with decent volume and sizeable spreads, and its underlying liquidity is good. It charges a middling fee for a niche fund, which may give it an edge over its more expensive rival, BBC.

SBIO MSCI ESG Analytics Insight

The MSCI ESG Fund Quality Score measures the ability of ETF underlying holdings to manage key medium to long-term risks and opportunities arising from environmental, social, and governance factors, as determined by MSCI ESG Research LLC. As of May 21, 2019 the ALPS Medical Breakthroughs ETF MSCI ESG Fund Quality Score is 2.01 out of 10.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. SBIO ranks in the 4th percentile within its peer group and in the 2nd percentile within the global universe of all funds in MSCI ESG Fund Metrics coverage.

SBIO CHARTS AND PERFORMANCE

Price Chart ($)
Total Return Chart (%)
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
COMPARE
RESET
Select ETFs to compare their performance:
PERFORMANCE [as of 05/21/19] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
SBIO 1.43% 3.24% 21.32% -4.69% 14.61% -- --
SBIO (NAV) 1.31% 3.24% 20.90% -4.45% 14.64% -- --
N/A -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

SBIO Top 10 Countries

SBIO Top 10 Sectors

SBIO Top 10 Holdings [View All]

SBIO Summary Data

SS&C
ALPS
12/31/14
Open-Ended Fund
0.50%
$179.30M
$1.28M
0.16%

SBIO Portfolio Data

$2.67B
-15.76
4.23
2.30%
12/19/19
66

SBIO Index Data

Market Cap
Fundamental
N/A

SBIO Portfolio Management

0.50%
--
--
--

SBIO Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

SBIO Fund Structure

Open-Ended Fund
No
Yes
100% / 0%
N/A
N/A
Low
Daily
Cboe Book Viewer
TOP OF BOOK
LAST 10 TRADES
Bats BZX Real-time Quote -
Daily Spread
Premium/Discount
Volume

SBIO Factset Analytics Block Liquidity

As of 05/22/19
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of SBIO. SBIO is rated a 5 out of 5.

SBIO Tradability

36,715
$1.28M
34,502
$1.19M
0.16%
$0.06
0.00%
0.28% / -0.32%
None
100.00%
50,000
0.69
0.03%
0.31%
918
$34.13
5

SBIO Sector/Industry Breakdown


SBIO
Segment Benchmark
92.26%
--
2.72%
--

SBIO Countries


SBIO
Segment Benchmark
89.96%
--
5.23%
--
4.11%
--
0.70%
--

SBIO Regions


SBIO
Segment Benchmark
89.96%
--
10.04%
--

SBIO Economic Development


SBIO
Segment Benchmark
100.00%
--

SBIO Performance Statistics

--
--
--
--
0.00%
N/A

SBIO MSCI ESG Ratings

2.01 / 10
3.85
1.84
--
5.82%
25.75

SBIO BENCHMARK COMPARISON HOLDINGS

66
--
--
0.00%

SBIO BENCHMARK COMPARISON SUMMARY


SBIO
Segment Benchmark
66
--
$2.67B
--
-15.76
--
4.23
--
0.00%
--
Medium
High

SBIO BENCHMARK COMPARISON MARKET CAP SIZE


SBIO
Segment Benchmark
0.00%
--
35.50%
--
50.51%
--
13.99%
--